Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Assessing aCCess to Investigations in Inflammatory Bowel Disease (ACCID): results from an international survey

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Decreased number of colonic tuft cells in quiescent ulcerative colitis patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Bacterial infections in acute pancreatitis

    Research output: Contribution to journalEditorialResearchpeer-review

  3. The prevention and management of Crohn's disease postoperative recurrence: results from the Y-ECCO/ClinCom 2019 Survey

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Enhanced processing of von Willebrand factor reflects disease severity and discriminates severe portal hypertension in cirrhosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Letter: the clinical course of Crohn's disease-the Sicilian experience. Authors' reply

    Research output: Contribution to journalLetterResearchpeer-review

  2. Praktisk anvendelse af thiopuriner hos patienter med kronisk inflammatoriske tarmsygdomme

    Research output: Contribution to journalReviewResearchpeer-review

  3. Histological Inflammation in the Endoscopically Uninflamed Mucosa is Associated With Worse Outcomes in Limited Ulcerative Colitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Nik S Ding
  • Tanya Lee
  • Dominik Bettenworth
  • Isabelle Cleynen
  • Nuha A Yassin
  • Johan Burisch
  • Alessandro Armuzzi
  • Marc Ferrante
  • Edyta Zagorowicz
  • John Mansfield
  • Krisztina Gesce
  • Javier P Gisbert
  • Timothy Raine
View graph of relations

BACKGROUND: Multiple investigations are available to aid the diagnosis and monitoring of disease activity in inflammatory bowel disease (IBD). Fecal calprotectin (FC) is an established surrogate for intestinal inflammatory activity. Therapeutic drug monitoring (TDM) including thiopurine metabolites, anti-tumor necrosis factor (TNF) levels and antidrug antibody measurements are a step toward personalized medicine in IBD, but face access barriers. We aimed to assess test availability and barriers for these investigations in European practice.

METHODS: Five-hundred questionnaires were distributed to workshop participants at the 11th Congress of the European Crohn's and Colitis Organisation (ECCO). Access to FC, TDM for thiopurines and anti-tumor necrosis factor agents, as well as factors associated with usage and barriers to access were recorded.

RESULTS: Responses were obtained from 195 attendees from 38 countries across a range of practices, healthcare settings and levels of experience. FC was available to 92.3% while access to anti-TNF (78.9%, P = 0.02 vs.  thiopurine TDM, P = 0.0002 vs.  FC) and thiopurine TDM (67.7%, P = 0.0001) were less widespread. Cost was a frequently cited barrier to test access or usage, with access having a significant West-East and North-South divide across all three investigations. The strongest independent predictor of access to all tests was healthcare spending per capita (P = 0.005 for FC; P < 0.0001 for both TDM).

CONCLUSION: FC, anti-TNF and thiopurine TDM are increasingly incorporated as part of routine practice in IBD care across Europe and have the potential to impact positively on patient care. However, access barriers remain of which we found test cost the most significant with the investment required to reduce these barriers.

Original languageEnglish
JournalEuropean journal of gastroenterology & hepatology
Issue number1S Suppl 1
Pages (from-to)e837-e842
Publication statusPublished - 1 Dec 2021

Bibliographical note

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

ID: 72506156